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Background: In gastric cancer, poor prognosis is associated with peritoneal dissemination, 
which often accompanies malignant ascites. We searched for a target molecule in peritoneal 
metastasis and investigated its clinical utility as a biomarker.
Methods: Biopsy specimens from both primary lesions and peritoneal metastasis, and if pos-
sible, malignant ascites, were obtained from 40 patients with gastric cancer. Vascular endothelial 
growth factor (VEGF) expression was analyzed by immunohistochemical staining and enzyme-
linked immunosorbent assay.
Results: VEGF expression was seen in 70% of peritoneal samples. Of the 40 patients, 35 had 
malignant ascites. These 35 patients were divided into two groups: 15 with ascites found beyond 
the pelvic cavity (large group) and 20 whose ascites were within the pelvic cavity (small group). 
The two groups did not significantly differ by serum VEGF levels, but ascites VEGF levels 
in the large group were significantly higher than in the small group (P , 0.0001). Serum VEGF 
and ascites VEGF levels were highly correlated in the large group (r = 0.686). A high ascites 
VEGF level was found to be a risk factor for survival (P = 0.045). We include a report of a 
patient with chemoresistant refractory gastric cancer and symptomatic ascites who obtained 
8 months of palliation from systemic bevacizumab.
Conclusion: Anti-VEGF therapies are promising, and the ascites VEGF level is an important 
marker in managing patients with gastric cancer and peritoneal metastasis.
Keywords: vascular endothelial growth factor, malignant ascites, peritoneal metastasis, gastric 
cancer, bevacizumab
Introduction
Peritoneal metastasis is the most life-threatening type of metastasis in gastric cancer.1,2 
Recent advances in systemic chemotherapy regimens that combine novel antineoplastic 
agents have shown encouraging tumor response rates and survival for patients with 
unresectable or metastatic gastric cancer.3–5 However, the prognosis of patients with 
peritoneal metastasis includes a median survival time of only 3–6 months.6,7
Several processes are associated with formation of peritoneal metastasis in gastric 
cancer, including cancer cell attachment, invasion, and proliferation in the peritoneum,8 
which are mediated by cytokines, proteases, growth factors, and angiogenic factors.
Vascular endothelial growth factor (VEGF) is a multifunctional cellular fac-
tor which can induce neovascularization and increase capillary permeability.9,10 
 Accordingly, VEGF is implicated in peritoneal metastasis of gastric cancer and 





subsequent development of malignant ascites, as well as 
ovarian cancer.11,12 By increasing abdominal pressure due to 
malignant ascites, severe symptoms, such as abdominal pain, 
nausea, anorexia, dyspnea, and cachexia decrease quality of 
life, and even reduce survival.13
Aoyagi et al, using primary tumor specimens, found 
that VEGF expression correlated with peritoneal metastasis 
in gastric cancer and appeared to be an essential element in 
development of peritoneal metastasis.14 However, no reports 
provide evidence based on peritoneal metastatic specimens 
themselves. In the present study, we evaluated VEGF expres-
sion immunohistochemically, with paired primary gastric 
cancer and peritoneal metastasis specimens.
Conversely, increased serum VEGF levels are associated 
with advanced tumor stage and can be used as a prognos-
tic biomarker in a variety of malignancies.15–17 In gastric 
cancer, serum VEGF levels were also significantly higher 
in patients with advanced-stage cancer, higher lymph node 
ratio, and perineural invasion,18 whereas such correlations 
with ascites VEGF levels were unclear. To understand bet-
ter the relationship between VEGF levels and malignant 
ascites, we analyzed and compared VEGF concentrations 
using an enzyme-linked immunosorbent assay for serum 
and malignant ascites of individual gastric cancer patients 
with peritoneal metastasis. VEGF concentration was also 




Between 2002 and 2010, 64 patients with gastric cancer and 
peritoneal dissemination were treated at Kanazawa University 
Hospital. Forty patients underwent both gastroendoscopy and 
laparoscopy, and biopsy specimens were taken from both pri-
mary tumor and peritoneal metastases. Each biopsy specimen 
was fixed in 10% neutral buffered formalin and embedded 
in paraffin; if possible, ascetic effusions and serum samples 
were centrifuged at 1,000× g for 10 minutes and stored at 
−80°C until analysis.
immunohistochemical staining
Human epidermal growth factor receptor 2 (HER2), and 
VEGF were analyzed using immunohistochemical staining 
with an  EnVision™ system (Dako, Carpinteria, CA, USA), 
which uses dextran polymers conjugated with horseradish 
peroxidase to avoid any endogenous biotin contamination. 
Sections were deparaffinized in xylene and rehydrated in a 
graded ethanol series. Endogenous peroxidase was blocked 




 in 100% methanol for 
20 minutes at room temperature. Sections were then incubated 
with primary antibody in a humidified chamber at 4°C over-
night. As the primary antibody, we used mouse monoclonal 
antibody CB11 (Invitrogen, Carlsbad, CA, USA) for HER2, 
diluted at 1:50, mouse monoclonal antibody pY992 (Invitro-
gen) for epidermal growth factor receptor, diluted at 1:50, and 
rabbit polyclonal antibody A-20 (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) for VEGF, diluted at 1:200. Peroxidase 
activity was detected with enzyme substrate 3-amino-9-ethyl 
carbazole. For negative controls, sections were incubated with 
Tris-buffered saline without primary antibodies. Samples in 
which $10% of tumor cells were slightly counterstained with 
Mayer’s hematoxylin were defined as positive.
Enzyme-linked immunosorbent assay
A quantitative sandwich enzyme-linked immunosorbent 
assay with a Quantikine human VEGF immunoassay kit 
(R&D Systems, Minneapolis, MN, USA) was used in accor-
dance with the manufacturer’s instructions, to measure VEGF 
in ascites and serum from patients with peritoneal metastasis. 
The assay quantity limit was 9.0 pg/mL. All experiments 
were performed in triplicate.
clinical trial
Patients with refractory peritoneal metastases of gastric cancer 
and symptomatic ascites resistant to systemic chemotherapy 
and intraperitoneal docetaxel were treated with single-agent 
bevacizumab. Bevacizumab was initiated at 5 mg/kg intrave-
nously, every 2 weeks if necessary, for palliation of symptoms. 
The local committee approved the study protocol (Kanazawa 
University Hospital, acceptance number 5608) and written 
informed consent was obtained from the patient.
statistical analysis
The Mann–Whitney U test was used to compare different 
groups for continuous and categorical variables. Correlations 
were analyzed by Pearson and Spearman coefficient analysis. 
Survival rates were calculated with the Kaplan–Meier method 
and differences were evaluated by log-rank test. P , 0.05 was 
considered to be statistically significant. All statistics were 
carried out using Statistical Package for the Social Sciences 
version 10 software (SPSS Inc., Chicago, IL, USA).
Results
VegF expression in gastric cancer
Forty pairs of primary tumor and peritoneal metasta-
ses were immunohistochemically examined for HER2, 
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 epidermal growth factor receptor, and VEGF expression. 
 Immunoreactivity for HER2 was recognized in cell mem-
branes; positive staining was found in 15% (6/40) of primary 
tumors and 3% (1/40) of peritoneal metastases. Epidermal 
growth factor receptor was also observed in cell membranes; 
positive staining was seen in 18% (7/40) of primary tumors 
and 3% (1/40) of peritoneal metastases. In contrast, VEGF 
diffusely stained the cytoplasm of cancer cells (Figure 1); 
positive tumor staining was seen in 85% (34/40) of primary 
tumors and 70% (28/40) of peritoneal metastases.
Association between VEGF levels and 
clinicopathological characteristics
Of the 40 patients, 35 had malignant ascites; therefore, 
35 pairs of ascites and serum samples were analyzed to 
quantify VEGF levels. Relationships between VEGF levels 
and clinicopathological variables are shown in Table 1. When 
patients were grouped as P1–2 and P3 according to the criteria 
of the Japanese Research Society for Gastric Cancer,19 no 
significant association between peritoneal metastatic grade 
and VEGF level was seen in either serum or ascites. The 
35 patients were divided into two groups based on whether 
ascites was found beyond the pelvic cavity or not. The 
15 patients with ascites beyond the pelvic cavity were clas-
sified as the large group and other 20 patients were classified 
as the small group. The two groups did not significantly differ 
for serum VEGF levels, but did significantly vary for ascites 
VEGF levels (P , 0.0001). The median ascites VEGF level 
in the small group was 504 (range 82–7,261) pg/mL; for the 
large group, it was 700 (range 231–7,113) pg/mL. VEGF 
levels in both serum and ascites showed no association with 
gender, age, or prior gastrectomy. Ascites VEGF levels and 
serum VEGF levels correlated in the large group (r = 0.686, 
P = 0.0034) but not in the small group (Figure 2).
Prognostic factors for overall survival
In the present study, we established cutoff values for serum 
VEGF (472 pg/mL) and ascites VEGF (660 pg/mL) using 
median values. The relationship between VEGF levels, vol-
ume of ascites, and peritoneal metastatic grade was evaluated 
using the Kaplan–Meier method. Univariate log-rank analysis 
showed that high ascites VEGF levels reduced overall survival 
(P = 0.041, Figure 3). Neither ascites volume nor peritoneal 
metastatic grade showed an association with overall survival. 
Serum VEGF levels also provided no significant evidence 
with regard to overall survival. Cox regression analysis 
showed ascites VEGF levels as a risk factor for survival 
(hazards ratio 2.21, 95% confidence interval 1.015–4.794, 
P = 0.045, Table 2).
case report
Our patient was a 62-year-old female diagnosed with 
type 4 gastric cancer, whose clinical course has been par-
tially reported previously by our colleague.20 Exploratory 
laparoscopy revealed severe peritoneal metastasis with 
malignant ascites. The patient received two cycles of S-1 
plus intraperitoneal docetaxel; disappearance of her perito-
neal metastasis was confirmed by second-look laparoscopy. 
Subsequently, the patient underwent total gastrectomy with 
D2 lymph node dissection which completed an R0 resection. 
Eighteen months after surgery, the patient’s cancer recurred 
and was treated with four cycles of weekly paclitaxel, while 
the patient suffered from symptomatic ascites requiring fre-
quent  paracenteses. Because of lack of response, the patient 
was administered bevacizumab monotherapy (5 mg/kg) 
intravenously. Despite only one administration, the patient 
noted an improvement in abdominal distention and required 
no paracenteses. After bevacizumab therapy, the patient 
received eight cycles of weekly paclitaxel. She died of aspi-
ration pneumonia due to ileus (Figure 4).
Discussion
Previous reports have implied that VEGF is associated with 
tumor progression including peritoneal metastasis; however, 
most of these reports are based in a xenograft model and 
the status of the primary tumor.14,21–23 In the present study, 
expression of VEGF was found not only in primary gastric 
tumors but also in peritoneal metastases, and more frequently 
than either HER2 or epidermal growth factor receptor. 
Establishment of peritoneal metastasis needs a multistep 
process involving detachment of cancer cells from their 
primary tumor, their attachment to the peritoneal surface, 
infiltration into the subperitoneal space, and proliferation 
with angiogenesis.8 VEGF secreted from cancer cells might 
enhance tumor growth by inducing an angiogenic response 
in the peritoneal microenvironment. We showed that VEGF 
A B
Figure 1 representative images of vascular endothelial growth factor immunostaining 
in gastric cancer tissues. (A) Diffusely stained cytoplasm of cancer cells in primary 
tumor. (B) Strongly stained cytoplasm of cancer cells (black arrow) and fibroblasts 
(white arrow) in peritoneal tumor.





is a convincing molecular target for peritoneal metastases. 
This is the first report to have formed the basis of clinical 
specimens from peritoneal tumors.
Malignant ascites with peritoneal metastasis seriously 
affects patients’ quality of life. VEGF mediates formation 
of malignant ascites by increasing the permeability of blood 
vessels.6 In this study, levels of circulating VEGF were not 
correlated with volume of ascites, because circulating VEGF 
can derive from both a primary tumor and peritoneal metas-
tases, and may depend on total tumor volume. Conversely, 
VEGF concentration in the ascites statistically correlated with 
ascites volume. VEGF may be produced by human peritoneal 
mesothelial cells when stimulated by basic fibroblast growth 
factor secreted from cancer cells and other human peritoneal 
mesothelial cells in the microenvironment.24 Thus, human 
peritoneal mesothelial cells are critical to accumulation of 
malignant ascites through production of diffusible VEGF. 
In addition to human peritoneal mesothelial cells, intrap-
eritoneal VEGF may come from various sources, such as 
 subperitoneal capillaries, peritoneal metastatic tumor, fibro-
blasts,25 and macrophages,26 whereas intraperitoneal VEGF 
cannot transfer into the systemic circulation due to capillary 
hyperpermeability. Accordingly, ascites volume correlates 
with ascites VEGF concentration. This result agrees with a 
previous report by Rudlowski et al, who showed the same 
findings in patients with ovarian cancer.27
In the present study, the prognostic value of VEGF levels 
was also assessed. Although several studies have shown 
that tumor VEGF is an independent prognostic factor in 
gastric cancer, measurement of VEGF levels both in serum 
and ascites is technically simple, does not require a tumor 
specimen, and is more objective in its evaluation than semi-
quantitative immunohistochemistry.28–30 Increased serum 
VEGF levels have been associated with advanced stage, 
higher lymph node metastasis, and perineural invasion in 
gastric cancer.31,32 These data suggest that anti-VEGF ther-
apy might have an effect on gastric cancer. Although Shah 
































Figure 2 Correlation of vascular endothelial growth factor levels between serum and ascites. There was a good correlation in the large group.
Notes: Patients were divided into two groups. Large group, ascites found beyond pelvic cavity; small group, ascites within pelvic cavity.
Table 1 Relationship between vascular endothelial growth factor levels and clinicopathological variables
Patients (n) s-VEGF (pg/mL)* P-value a-VEGF (pg/mL)* P-value
Age (years)
,62 14 408 (90–1191) 0.108 572 (82–7261) 0.538
$62 21 440 (23–1337) 616 (84–3216)
Gender
Male 15 440 (90–1337) 0.752 616 (148–3216) 0.333
Female 20 408 (23–1191) 571 (82–7113)
P grade‡
P1, P2 16 405 (90–1337) 0.043 504 (82–7261) 0.298
P3 19 473 (183–1337) 660 (84–7113)
Ascitic
Volume†
 small 20 405 (90–1337) 0.331 504 (82–7261) ,0.0001
 large 15 440 (23–7113) 660 (84–7113)
Gastrectomy
Yes 6 382 (90–675) 0.064 504 (82–571) 0.023
no 29 472 (183–1337) 660 (84–7261)
Notes: *Values are median (range); ‡according to the Japanese Gastric Cancer Association; †according to whether ascites is found beyond the pelvic cavity or not. 
Abbreviations: s-VEGF, serum vascular endothelial growth factor; a-VEGF, ascitic vascular endothelial growth factor.
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combined with chemotherapy might be a promising therapy 
for patients with metastatic or unresectable gastric and 
 gastroesophageal junction adenocarcinoma,33 a randomized, 
double-blind, placebo-controlled, Phase III study (Avastin 
in Gastric Cancer) failed to establish evidence about the 
usefulness of bevacizumab in gastric cancer.34 Moreover, 
Vidal et al found that a high preoperative serum VEGF 
level was an independent prognostic factor for recurrence 
and survival after R0 resection of gastric cancer.18 However, 
we could not find a significant association between serum 
VEGF level and overall survival. This might be the reason 
why that all the patients in our study were in stage IV with 
peritoneal metastasis and did not receive R0 resection. In 
contrast, the prognostic significance of ascites VEGF level 
has not been adequately studied. To our knowledge, this is 
the first study to report that elevated ascites VEGF levels 
are significantly associated with shorter overall survival 
in gastric cancer. The principal mechanisms explaining 
the prognostic significance of VEGF are tumor expansion 
and massive ascites, which cause severe symptoms, such 
as bowel obstruction, dyspnea, and cachexia. Additionally, 
VEGF in malignant ascites may induce immune suppres-
sion in cancer by inhibiting dendritic cell maturation35 
and increasing tumor-infiltrating regulatory T cells.36 
 Furthermore, high ascites VEGF levels may be associ-
ated with upregulation of multidrug resistance-associated 
protein, leading to resistance to platinum-based treatment, 
which is often used in unresectable gastric cancer.37,38 In 
any case, anti-VEGF therapies should be considered for 























Figure 3 Kaplan–Meier survival curves for overall survival rate according to vascular endothelial growth factor concentration in ascites.
Note: The high ascites vascular endothelial growth factor concentration subgroup showed a shorter overall survival than the low concentration subgroup (P = 0.041).
Table 2 cox regression analysis
Event Patients (n) MST HR 95% CI P-value
P grade*
P1, P2 16 433 1.671 0.796–3.509 0.175
P3 19 301
Volume of ascites‡
small 20 387 1.615 0.766–3.408 0.208
large 15 317
s-VEGF levels
low 18 390 1.609 0.778–3.327 0.199
high 17 252
a-VEGF levels
low 18 487 2.206 1.015–4.794 0.045
high 17 345
Note: *According to the Japanese Gastric Cancer Association; ‡according to whether ascites is found beyond the pelvic cavity or not.
Abbreviations: s-VEGF, serum vascular endothelial growth factor; a-VEGF, ascitic vascular endothelial growth factor; MST, median survival time; HR, hazards ratio; CI, 
confidence interval.





Our patient experienced successful palliation of 
 symptomatic ascites using intravenous (systemic) 
 bevacizumab. Several studies using mouse models indicate 
that intraperitoneal (regional) bevacizumab could be useful 
for peritoneal metastasis.23,39 In clinical case reports, beva-
cizumab was also administrated regionally for patients with 
malignant ascites.40,41 Yagi et al reported that bevacizumab 
had a more pronounced effect on malignant ascites and 
peritoneal nodules when administered systemically rather 
than regionally.42 If bevacizumab is administered regionally, 
most of the antibody will be neutralized in malignant ascites, 
which contains large amounts of VEGF, resulting in a low 
blood concentration. These results support the use of systemi-
cally administered bevacizumab, with ascites removed before 
treatment for more efficacy.
In conclusion, VEGF might be correlated with the devel-
opment of peritoneal metastasis and malignant ascites. The 
ascites VEGF level appears to be an important prognostic 
indicator in gastric cancer with peritoneal metastasis. Fur-
ther prospective studies will be necessary to validate both 
ascites VEGF as a predictive marker of poor outcome and 
the efficacy of bevacizumab for chemoresistant malignant 
ascites.
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Figure 4 Treatment and disease progression for the presented case.
Abbreviations: PTX, paclitaxel; CY, cytology (peritoneal); DOC-ip, intraperitoneal docetaxel; iv, intravenously; mm/yy, month/year.
OncoTargets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal
OncoTargets and Therapy is an international, peer-reviewed, open access 
journal focusing on the pathological basis of all cancers, potential 
targets for therapy and treatment protocols employed to improve the 
management of cancer patients. The journal also focuses on the impact 
of management programs and new therapeutic agents and protocols on 
patient perspectives such as quality of life, adherence and satisfaction. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.





Prognostic significance of VEGF in ascites
 12. Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap 
decreases tumor burden, inhibits ascites, and causes dramatic vascular 
remodeling in an ovarian cancer model. Clin Cancer Res. 2003;9(15): 
5721–5728.
 13. Sherer DM, Eliakim R, Abulafia O. The role of angiogenesis in the accu-
mulation of peritoneal fluid in benign conditions and the development 
of malignant ascites in the female. Gynecol Obstet Invest. 2000;50(4): 
217–224.
 14. Aoyagi K, Kouhuji K, Yano S, et al. VEGF significance in peritoneal 
recurrence from gastric cancer. Gastric Cancer. 2005;8(3):155–163.
 15. Li L, Wang L, Zhang W, et al. Correlation of serum VEGF levels with 
clinical stage, therapy efficacy, tumor metastasis and patient survival 
in ovarian cancer. Anticancer Res. 2004;24(3b):1973–1980.
 16. Kaya A, Ciledag A, Gulbay BE, et al. The prognostic significance of 
vascular endothelial growth factor levels in sera of non-small cell lung 
cancer patients. Respir Med. 2004;98(7):632–636.
 17. Alabi AA, Suppiah A, Madden LA, Monson JR, Greenman J. 
 Preoperative serum vascular endothelial growth factor-a is a marker for 
subsequent recurrence in colorectal cancer patients. Dis Colon Rectum. 
2009;52(5):993–999.
 18. Vidal O, Metges JP, Elizalde I, et al. High preoperative serum vascular 
endothelial growth factor levels predict poor clinical outcome after cura-
tive resection of gastric cancer. Br J Surg. 2009;96(12):1443–1451.
 19. Japanese Research Society for Gastric Cancer. Japanese Classification 
of Gastric Carcinoma. 1st English ed. Tokyo, Japan: Kanehara; 1995.
 20. Kinoshita J, Fushida S, Makino I, et al. [The use of bevacizumab in 
refractory peritoneal dissemination of gastric cancer with malignant 
ascites – two case reports.] Gan To Kagaku Ryoho. 2011;38(12): 
2360–2362. Japanese.
 21. Kamiyama M, Ichikawa Y, Ishikawa T, et al. VEGF receptor antisense 
therapy inhibits angiogenesis and peritoneal dissemination of human 
gastric cancer in nude mice. Cancer Gene Ther. 2002;9(2):197–201.
 22. Baba M, Konno H, Maruo Y, et al. Relationship of p53 and vascular 
endothelial growth factor expression of clinicopathological factors in 
human scirrhous gastric cancer. Eur Surg Res. 1998;30(2):130–137.
 23. Imaizumi T, Aoyagi K, Miyagi M, Shirouzu K. Suppressive effect 
of bevacizumab on peritoneal dissemination from gastric cancer in a 
peritoneal metastasis model. Surg Today. 2010;40(9):851–857.
 24. Sako A, Kitayama J, Yamaguchi H, et al. Vascular endothelial growth 
factor synthesis by human omental mesothelial cells is augmented by 
fibroblast growth factor-2: possible role of mesothelial cell on the devel-
opment of peritoneal metastasis. J Surg Res. 2003;115(1):113–120.
 25. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial 
growth factor is induced in response to transforming growth factor-beta in 
fibroblastic and epithelial cell. J Biol Chem. 1994;269(9):6271–6274.
 26. Hermey JH, Dimitriadis E, Kay E, Rdmond HP, Bouchier-Hayes D. 
Regulation of macrophage production of vascular endothelial growth 
factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann 
Surg Oncol. 1998;5(3):271–278.
 27. Rudlowski C, Pickart AK, Fuhljahn C, et al. Prognostic significance 
of vascular endothelial growth factor expression in ovarian cancer 
patients: a long-term follow-up. Int J Gynecol Cancer. 2006;16 Suppl 1: 
S183–S189.
 28. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular 
endothelial growth factor expression in gastric carcinoma. Cancer. 
1996;77(5):858–863.
 29. Saito H, Tsujitani S, Kondo A, Ikeguchi M, Maeta M, Kaibara N. 
 Expression of vascular endothelial growth factor correlates with hematog-
enous recurrence in gastric carcinoma. Surgery. 1999;125(2):195–201.
 30. Ichikura T, Tomimatsu S, Ohkura E, Mochizuki H. Prognostic sig-
nificance of the expression of vascular endothelial growth factor 
(VEGF) and VEGF-C in gastric carcinoma. J Surg Oncol. 2001;78(2): 
132–137.
 31. Karayiannakis AJ, Syrigos KN, Polychrondis A, et al. Circulating 
VEGF levels in the serum of gastric cancer patients: correlation with 
pathological variables, patient survival, and tumor surgery. Ann Surg. 
2002;236(1):37–42.
 32. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, 
Yanoma S. Plasma concentration of VEGF and b-FGF in patients with 
gastric carcinoma. Cancer Lett. 2000;153(1–2):7–12.
 33. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter Phase II study 
of irinotecan, cisplatin, and bevacizumab in patients with metastatic 
gastric or gastroesophaeal junction adenocarcinoma. J Clin Oncol. 
2006;24(33):5201–5206.
 34. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination 
with chemotherapy as first-line therapy in advanced gastric cancer: 
a randomized double-blind, placebo-controlled phase III study. J Clin 
Oncol. 2011;29(30):3968–3976.
 35. Della Porta M, Danova M, Rigolin GM, et al. Dendritic cells and vas-
cular endothelial growth factor in colorectal cancer: correlations with 
clinicopathological findings. Oncology. 2005;68(2–3):276–284.
 36. Li B, Lalani AS, Harding TC, et al. Vascular endothelial growth fac-
tor blockade reduces intratumoral regulatory T cells and enhances the 
efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer 
Res. 2006;12(22):6808–6816.
 37. Bamias A, Koutsoukou V, Terpos E, et al. Correlation of NK T-like 
CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF 
and TNFa in ascites from advanced ovarian cancer: association with 
platinum resistance and prognosis in patients receiving first-line, 
 platinum-based chemotherapy. Gynecol Oncol. 2008;108(2):421–427.
 38. Zhang XS, Zhu XF, Gao JS, et al. Multiple drug resistance phenotype 
of human endothelial cells induced by vascular endothelial growth 
factor 165. Acta Pharmacol Sin. 2001;22(8):731–735.
 39. Ninomiya S, Inomata M, Tajima M, et al. Effect of bevacizumab mono-
clonal antibody to vascular endothelial growth factor, on peritoneal 
matastasis of MKN-45P human gastric cancer in mice. J Surg Res. 
2009;154(2):196–202.
 40. Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of 
bevacizumab to palliate symptomatic ascites in patients with refractory 
ovarian carcinoma. Gynecol Oncol. 2006;102(3):425–428.
 41. Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, 
Rose S. Intraperitoneal bevacizumab for the palliation of malignant 
ascites in refractory ovarian cancer. Gynecol Oncol. 2008;111(3): 
530–532.
 42. Yagi Y, Fushida S, Harada S, et al. Biodistribution of humanized anti-
VEGF monoclonal antibody/bevacizumab on peritoneal metastatic 
models with subcutaneous xenograft of gastric cancer in mice. Cancer 
Chemother Pharmacol. 2010;66(4):745–753.
